Flare Therapeutics Inc. – Trademark Portfolio

Entity Type: 03

Flare Therapeutics Inc. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 3 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 4 Nice Classification classes. Currently, 0 trademarks are registered and 3 are pending. The owner is based in Cambridge, MA.

215 First Street, Ste. 150

Cambridge, MA 02142

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Flare Therapeutics Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (3 filings)

Scientific and technological services; industrial analysis and research services

5
Pharmaceuticals (3 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

40
Treatment & Processing (3 filings)

Treatment of materials

44
Medical Services (2 filings)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

Frequently Asked Questions

How many trademarks does Flare Therapeutics Inc. have?

Flare Therapeutics Inc. has 4 U.S. trademarks filed with the USPTO. Of these, 3 pending, 1 abandoned.

What trademark classes does Flare Therapeutics Inc. file in?

Flare Therapeutics Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 44 (Medical Services). Class 42 covers scientific and technological services; industrial analysis and research services.

What is Flare Therapeutics Inc.'s trademark registration success rate?

Flare Therapeutics Inc. has a 0% trademark registration rate, with 0 out of 1 resolved applications resulting in successful registration. Currently, 3 applications are pending review.